Human CD20 Full-Length Proteins

CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an appropriate CD20 protein on the market for detecting the CD20-CAR expression and the bioactivity of antibody drugs.

To tackle these challenges, ACROBiosystems has designed the full-length multi-transmembrane CD20 proteins, produced by HEK293 cells and insect cells. The bioactivity and purity of the full-length CD20 protein were confirmed by ELISA, SDS-PAGE, and SPR. In addition, ACROBiosystems provides full-length CD20 protein for immunization and assessment of CD20-CAR expression.

Application

Human CD20 Full-Length Proteins

Product List

Molecule Cat. No. Host Product Description
CD20/ MS4A1 CD0-H52H3 HEK293 Human CD20/ MS4A1 Full Length Protein, His Tag
CD0-H55Ha Insect cells-HI5 Human CD20/ MS4A1 Full Length Protein, His Tag

 

Product Features

Full-length CD20 protein fully complies with both small and big loops.

Full-length CD20 protein fully complies with both small and big loops.

Image Credit: ACROBiosystems

Full-length CD20 protein has better bioactivity.

  1. HEK293 Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL. Image Credit: ACROBiosystems

  1. Insect Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL.

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL. Image Credit: ACROBiosystems

  1. Escherichia coli (Extracellular)

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL.

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL. Image Credit: ACROBiosystems

The bioactivity of Full-Length CD20 Protein was verified by Elisa/SPR and the protocols are presented.

ELISA

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL. Image Credit: ACROBiosystems

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL.

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL. Image Credit: ACROBiosystems

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL. Image Credit: ACROBiosystems

SPR

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200). Image Credit: ACROBiosystems

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200). Image Credit: ACROBiosystems

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 29, 2024 at 6:46 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    FLAG - An ACROBiosystems Brand. (2024, January 29). Human CD20 Full-Length Proteins. News-Medical. Retrieved on June 23, 2024 from https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx.

  • MLA

    FLAG - An ACROBiosystems Brand. "Human CD20 Full-Length Proteins". News-Medical. 23 June 2024. <https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx>.

  • Chicago

    FLAG - An ACROBiosystems Brand. "Human CD20 Full-Length Proteins". News-Medical. https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx. (accessed June 23, 2024).

  • Harvard

    FLAG - An ACROBiosystems Brand. 2024. Human CD20 Full-Length Proteins. News-Medical, viewed 23 June 2024, https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.